Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the phar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta pharmacologica Sinica Jg. 43; H. 12; S. 3130 - 3138
Hauptverfasser:	Qian, Hong-jie, Wang, Yu, Zhang, Meng-qi, Xie, Yuan-chao, Wu, Qing-qing, Liang, Li-yu, Cao, Ye, Duan, Hua-qing, Tian, Guang-hui, Ma, Juan, Zhang, Zhuo-bing, Li, Ning, Jia, Jing-ying, Zhang, Jing, Aisa, Haji Akber, Shen, Jing-shan, Yu, Chen, Jiang, Hua-liang, Zhang, Wen-hong, Wang, Zhen, Liu, Gang-yi
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Singapore Springer Nature Singapore 01.12.2022 Nature Publishing Group Springer Singapore
Schlagworte:	Adverse events Biomedical and Life Sciences Biomedicine COVID-19 Dosage Drug development Immunology Internal Medicine Medical Microbiology Nucleoside analogs Oral administration Pharmacokinetics Pharmacology/Toxicology Safety Severe acute respiratory syndrome coronavirus 2 Vaccine pharmacokinetics SARS-CoV-2 VV116 healthy subjects nucleoside analog safety
ISSN:	1671-4083, 1745-7254, 1745-7254
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!